QQ客服 官方微博 反馈留言

	Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
	Zhang Shu[1]; Mao Xiao-Dong[2]; Wang Hai-Tao[3]; Cai Feng[4]; Xu Jing[5]
刊名	BMJ open
	2016
卷号	6页码:e011714
关键词	bevacizumab erlotinib meta-analysis non-small cell lung cancer
ISSN号	2044-6055
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/2236297
专题	上海大学
作者单位	1.[1]Department of Respiratory Medicine, Seventh People's Hospital of Shanghai University of TCM, Shanghai, China. 2.[2]Department of Chest Surgery, Seventh People's Hospital of Shanghai University of TCM, Shanghai, China. 3.[3]Department of Respiratory Medicine, Seventh People's Hospital of Shanghai University of TCM, Shanghai, China. 4.[4]Department of Respiratory Medicine, Seventh People's Hospital of Shanghai University of TCM, Shanghai, China. 5.[5]Department of Respiratory Medicine, Seventh People's Hospital of Shanghai University of TCM, Shanghai, China.
推荐引用方式 GB/T 7714	Zhang Shu[1],Mao Xiao-Dong[2],Wang Hai-Tao[3],et al. Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis[J]. BMJ open,2016,6:e011714.
APA	Zhang Shu[1],Mao Xiao-Dong[2],Wang Hai-Tao[3],Cai Feng[4],&Xu Jing[5].(2016).Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.BMJ open,6,e011714.
MLA	Zhang Shu[1],et al."Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis".BMJ open 6(2016):e011714.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。